-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$6.001076.47% Upside
Passage Bio, Inc. Frequently Asked Questions
-
What analysts cover Passage Bio, Inc.?
Passage Bio, Inc. has been rated by research analysts at Goldman Sachs in the past 90 days.